Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Universite De Montpellier currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 5 distinct examiners and 5 distinct art units, indicating a broad spread of examination across the USPTO. The lack of concentration suggests that prosecution strategies must be tailored to the specific preferences of multiple individual examiners rather than a single group.
The busiest examiner for this portfolio is SEAMAN, D MARGARET M, who is responsible for 1 pending office action. Because each of the 5 distinct examiners holds only a single action, the workload is perfectly balanced across the current docket. Practitioners should prepare for diverse procedural styles as no single examiner or art unit dominates the pending matters. This distribution across 5 distinct art units requires a flexible approach to address the varying standards within the Biotechnology & Pharmaceuticals sector, as each case may follow a unique path toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (75%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| LIU, CHU CHUAN | 1 | 71.3% | +14.9% |
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855427 | LIPOPEPTIDE COMPOUND AND TREATMENT OF PAIN DISORDER | O DELL, DAVID K | — |
| 18843732 | METHOD FOR DETERMINING A PARAMETER OF THE RESPONSE OF AN AUDITORY NERVE OF A SUBJECT AND ASSOCIATED METHODS AND DEVICES | LIU, CHU CHUAN | — |
| 18435619 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | HOWELL, THEODORE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855427 | LIPOPEPTIDE COMPOUND AND TREATMENT OF PAIN DISORDER | O DELL, DAVID K | — |
| 18843732 | METHOD FOR DETERMINING A PARAMETER OF THE RESPONSE OF AN AUDITORY NERVE OF A SUBJECT AND ASSOCIATED METHODS AND DEVICES | LIU, CHU CHUAN | — |
| 18435619 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | HOWELL, THEODORE R | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1692 | 1 |
| 3791 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18973608 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SEAMAN, D MARGARET M | 1625 | §102DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18855427 | LIPOPEPTIDE COMPOUND AND TREATMENT OF PAIN DISORDER | O DELL, DAVID K | 1692 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18843732 | METHOD FOR DETERMINING A PARAMETER OF THE RESPONSE OF AN AUDITORY NERVE OF A SUBJECT AND ASSOCIATED METHODS AND DEVICES | LIU, CHU CHUAN | 3791 | §101§102§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18435619 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | HOWELL, THEODORE R | 1628 | §101DP | Non-Final OA | — | Pending | Feb 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE MONTPELLIER has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
D Margaret M Seaman has the most, with 1 of UNIVERSITE DE MONTPELLIER's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
